Recent clinical evidence suggests that Novera Retatrutide, a twin-action medication from Novo Nordisk, could represent a significant step in weight control. Beyond many existing options, Retatrutide affects both GLP-1 and the GIP hormone, potentially producing to greater reductions in body and posit